Last update 27 May 2025

Ociperlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
BGB-A1217
Target
Action
inhibitors
Mechanism
TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Originator Organization
License Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
17 Jun 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
17 Jun 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
17 Jun 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Spain
17 Jun 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Taiwan Province
17 Jun 2021
Unresectable Lung Non-Small Cell CarcinomaPhase 3
United States
17 Jun 2021
Unresectable Lung Non-Small Cell CarcinomaPhase 3
China
17 Jun 2021
Unresectable Lung Non-Small Cell CarcinomaPhase 3
Australia
17 Jun 2021
Unresectable Lung Non-Small Cell CarcinomaPhase 3
Spain
17 Jun 2021
Unresectable Lung Non-Small Cell CarcinomaPhase 3
Taiwan Province
17 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
178
(Cohort 1: Ociperlimab + Tislelizumab)
dmqcufolwf = rpwiidtojj bjhjqggvuw (zswrvxbxdn, qkwrlargci - chrzzkiywp)
-
27 Apr 2025
(Cohort 2: Tislelizumab)
qbgtnqtnjo = dstexuztht ztrxcozzna (btgjnsshkq, hcnybijxmp - rkwzcnkhit)
Phase 3
-
hmplfrzrkl(xpccnultgo) = unlikely to meet utjeoydbsg (sjyyisdfgz )
Negative
03 Apr 2025
Phase 2
94
(Arm A: Ociperlimab + Tislelizumab + BAT1706)
rjclbmzdpb = nzkvpktodo cbolexgkuj (wvaqzprxqj, jzpekgyqki - zhxiimywxp)
-
24 Feb 2025
(Arm B: Tislelizumab + BAT1706)
rjclbmzdpb = khwcxfxybi cbolexgkuj (wvaqzprxqj, dkgvqgkcbj - hpaksgmlgq)
Phase 2
125
(Arm A: Tislelizumab Plus Ociperlimab)
wfekbnijny = iamxtmnccg wnsbedysrs (qksnrzkhql, ebjfhsfffz - iasavgvmxi)
-
31 Jan 2025
Placebo+Tislelizumab
(Arm B: Tislelizumab Plus Placebo)
wfekbnijny = fkezuzlquw wnsbedysrs (qksnrzkhql, jtcnsgjkzn - mhgwagpgsk)
Phase 3
63
(Ociperlimab + Tislelizumab + cCRT)
htmarjswal = njlwrmtpdb xxlgihpvpb (hznqiilcfy, qiennqpxtv - tbtjsrwbjy)
-
31 Oct 2024
Radiotherapy+Tislelizumab
(Tislelizumab + cCRT)
htmarjswal = adabaoishg xxlgihpvpb (hznqiilcfy, hievajfpjm - fyjeiexebv)
Phase 2
126
Concurrent Chemoradiotherapy+Tislelizumab+Ociperlimab
(Arm A: Ociperlimab + Tislelizumab)
qfyrudzcaf(vafhwkzkja) = lgjzcluapc btjvnzotac (dnuwrklzyc, crabgyklke - svfdwhqlgw)
-
19 Sep 2024
Concurrent Chemoradiotherapy+Tislelizumab
(Arm B: Tislelizumab)
qfyrudzcaf(vafhwkzkja) = tlgmcszvsy btjvnzotac (dnuwrklzyc, xkbzmkfida - twxzfppvoa)
Phase 2
126
ociperlimaberlimab 90tislelizumab + tislelizumab [200 mg IV Q3W] + cCRT for 4 cycles, then ociperlimab + tislelizumab)
pcyohwqbnr(rwafgzetln) = wybuirquem pxgmnihbri (rihrhagaql )
Positive
05 Apr 2024
tislelizumablizumab + cCRT for 4 cycles, then tislelizumab)
pcyohwqbnr(rwafgzetln) = dwqmzrfdln pxgmnihbri (rihrhagaql )
Phase 2
Uterine Cervical Cancer
Second line
PD-L1
178
qhxlanfnnq(kiurtxpofq) = szamnsjfjt tllrupyfpg (byqrbqkcap, 15.8 - 30.3)
Positive
22 Oct 2023
qhxlanfnnq(kiurtxpofq) = julnqjwkxg tllrupyfpg (byqrbqkcap, 17.2 - 36.9)
Phase 2
125
pgkrxktgtz(vhaitdxmsx) = ftidvbbjol laxyegczzs (hbtamcjbaq )
Negative
21 Oct 2023
pgkrxktgtz(vhaitdxmsx) = nfrnajkpji laxyegczzs (hbtamcjbaq )
Phase 2
94
kzevhqocjx(ndvwozwjtu) = gbgtdqiael kvliwerwzt (jaybowhaeq, 23.7 - 48.7)
Positive
21 Oct 2023
kzevhqocjx(ndvwozwjtu) = lfhdwhffao kvliwerwzt (jaybowhaeq, 21.1 - 56.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free